Business
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point
Alliance launches with 26 founding companies to develop a national strategy for U.S. biotechnology leadership BOCA RATON, Fla., May 13, 2026 (GLOBE NEWSWIRE)
About this update from Inmune Bio Inc.
[{"type":"text","content":"Alliance launches with 26 founding companies to develop a national strategy for U.S. biotechnology leadership BOCA RATON, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- INmune Bio, a clinical-stage biotechnology company developing treatments that harness the patient’s innate immune system to fight disease, today announced it has been named a founding member of the American Biotech Innovation Alliance (ABIA). The newly launched national coalition brings together biotechnology leaders with the shared objective of defining a national strategy to sustain and extend U.S. leadership in biotech innovation. As part of the ABIA, INmune Bio will collaborate with other industry leaders to address critical pressure points facing the sector, including manufacturing capacity, early-stage research investment, regulatory flexibility, and workforce development. \"INmune Bio is honored to join the American Biotech Innovation Alliance as a founding member,\" said David Moss, CEO of INmune Bio. \"The United States has historically been the global leader in biotechnology, but sustaining that edge requires proactive coordination, strategic capital formation, and a regulatory framework that supports mid-size and emerging innovators. We look forward to collaborating with our peers to strengthen the domestic innovation ecosystem and ensure that patient-centric therapies continue to advance without friction.\" The ABIA was established to address a shifting landscape where global competition, offshored supply chains, and market volatility threaten to erode the United States' historic advantage in medical discovery. The organization intends to build strategic alignment within the industry to draft a cohesive, forward-looking framework for policymakers, investors, and academia. \"We've spent decades building the world's leading biotech ecosystem, but we're now operating in a very different environment,\" said Patroski Lawson, Founder of the ABIA. \"If we don't start thinking more strategically about what comes next, we risk losing ground. We need to think long-term and work to protect American biotech. ABIA was created to bring leaders together to define that next phase and to turn those conversations into something actionable.\" INmune Bio joins a distinguished group of commercial-stage organizations, preclinical innovators, and ecosystem partners to shape the ABI...